<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28845/outcomes-from-resonate-trial-in-relapsed-cll?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Outcomes from RESONATE Trial in Relapsed CLL

Name: Outcomes from RESONATE Trial in Relapsed CLL
Uploaded: 2019-06-25T08:40:06
Duration: 1 min 54 s
Description: Paul M.Barr MD Associate Professor of Medicine at Wilmot Cancer Institute explains the results found of the RESONATE Trial that was evaluating ibrutinib versus ofatumumab in relapsed chronic lymphocytic leukemia (CLL).

00:01:54

Don

3 years 81 Views

Share Add to Report 0 0

Embed (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28845/outcomes-from-resonate-trial-in-relapsed-cll?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Embed (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://oncologytube.com/videoEmbed/28845/outcomes-from-resonate-trial-in-relapsed-cll?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit="></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://oncologytube.com/videoEmbed/28845/outcomes-from-resonate-trial-in-relapsed-cll?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Link (HTML):

<a href="https://oncologytube.com/v/28845?channelName=obr"><img src="https://oncologytubecom.cdn.ypt.me/videos/video_190625204006_6a35/video_190625204006_6a35.jpg?cache=15669161691678829655">Outcomes from RESONATE Trial in Relapsed CLL</a>

Link (BBCode):

[url=https://oncologytube.com/v/28845?channelName=obr][img]https://oncologytubecom.cdn.ypt.me/videos/video_190625204006_6a35/video_190625204006_6a35.jpg?cache=15669161691678829655[/img]Outcomes from RESONATE Trial in Relapsed CLL[/url]

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Chronic Lymphocytic Leukemia

Description:

Paul M.Barr MD Associate Professor of Medicine at Wilmot Cancer Institute explains the results found of the RESONATE Trial that was evaluating ibrutinib versus ofatumumab in relapsed chronic lymphocytic leukemia (CLL).